Aktis Oncology, Inc. (AKTS) stock
AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.15−0.25 (-1.52%)
Close on Nov 20, 2026Market cap $898.26MP/E –Yield –
Aktis Oncology free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$26.82M | – |
| Q2 FY2026 | Jun 30, 2026 | -$21.85M | – |
| Q1 FY2026 | Mar 31, 2026 | -$26.10M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.23M | – |
| Q2 FY2025 | Jun 30, 2025 | -$17.72M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.38M | – |
See a number that looks wrong?